Why the study?
Do ARBs improve outcomes and tolerability in patients with hypertension, CHF, or diabetic nephropathy compared to ACE inhibitors?
Population
Patients with hypertension, congestive heart failure (CHF), or Type 2 diabetes with nephropathy
Comparison
Angiotensin II receptor blockers (ARBs) vs Angiotensin converting enzyme inhibitors or…
Design
Review
Authors
Loading...
Supports ARB preference for tolerability in diabetes or HF; leaves open need for updated head-to-head RCTs.
Do ARBs improve outcomes and tolerability in patients with hypertension, CHF, or diabetic nephropathy compared to ACE inhibitors?
ARBs are an effective and well-tolerated alternative to ACE inhibitors for hypertension, with additional benefits in renoprotection and heart failure.
Sharon See (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: